{"result": "(\"entity\"<|>GLIFLOZIN<|>EVENT<|>Gliflozin is a medication that leads to an increase in glucagon concentrations in patients with diabetes.)\n##\n(\"entity\"<|>METFORMIN<|>EVENT<|>Metformin is a medication that inhibits hepatic gluconeogenesis and increases intracellular glucose synthesis.)\n##\n(\"entity\"<|>PIOGLITAZONE<|>EVENT<|>Pioglitazone is a medication that reduces insulin resistance and improves lipid profiles in patients with diabetes.)\n##\n(\"entity\"<|>SULFONYLUREAS<|>EVENT<|>Sulfonylureas are medications that increase insulin secretion from pancreatic beta cells.)\n##\n(\"entity\"<|>DPP4 INHIBITORS<|>EVENT<|>DPP4 inhibitors are medications that increase endogenous GLP-1 and GIP levels.)\n##\n(\"entity\"<|>MICROALBUMINURIA<|>EVENT<|>Microalbuminuria is a marker indicating higher blood pressure values over a 24-hour period.)\n##\n(\"entity\"<|>CARDIOVASCULAR DISEASE<|>EVENT<|>Cardiovascular disease refers to a range of conditions affecting the heart and blood vessels.)\n##\n(\"entity\"<|>TYPE 2 DIABETES MELLITUS<|>EVENT<|>Type 2 diabetes mellitus is a chronic condition that affects the way the body processes blood sugar (glucose).)\n##\n(\"entity\"<|>HYPERTENSION<|>EVENT<|>Hypertension is a condition in which the blood pressure in the arteries is persistently elevated.)\n##\n(\"entity\"<|>GLUCOSE<|>EVENT<|>Glucose is a simple sugar that is an important energy source in living organisms and is a component of many carbohydrates.)\n##\n(\"entity\"<|>TRIGLYCERIDES<|>EVENT<|>Triglycerides are a type of fat (lipid) found in your blood, which can affect heart health.)\n##\n(\"entity\"<|>HDL CHOLESTEROL<|>EVENT<|>HDL cholesterol is known as \"good\" cholesterol, which helps remove other forms of cholesterol from the bloodstream.)\n##\n(\"entity\"<|>GLUCAGON<|>EVENT<|>Glucagon is a hormone that raises blood glucose levels, counteracting the effects of insulin.)\n##\n(\"entity\"<|>GLUCOSE TRANSPORTERS<|>EVENT<|>Glucose transporters are proteins that facilitate the transport of glucose across the plasma membranes of cells.)\n##\n(\"entity\"<|>INSULIN<|>EVENT<|>Insulin is a hormone that regulates glucose levels in the blood and is crucial for the metabolism of carbohydrates, fats, and proteins.)\n##\n(\"entity\"<|>CIRCULATORY VARIABILITY<|>EVENT<|>Circadian variability refers to the fluctuations in physiological processes that occur in a 24-hour cycle.)\n##\n(\"entity\"<|>EVIDENCE<|>EVENT<|>Evidence refers to the data and findings that support medical conclusions and treatment efficacy.)\n##\n(\"entity\"<|>HEPATIC GLUCOSE PRODUCTION<|>EVENT<|>Hepatic glucose production is the process by which the liver produces glucose, particularly during fasting.)\n##\n(\"entity\"<|>GLYCOGEN SYNTHESIS<|>EVENT<|>Glycogen synthesis is the process of converting glucose into glycogen for storage in the liver and muscles.)\n##\n(\"entity\"<|>PERIPHERAL GLUCOSE UPTAKE<|>EVENT<|>Peripheral glucose uptake refers to the process by which cells take in glucose from the bloodstream.)\n##\n(\"entity\"<|>INSULIN SENSITIVITY<|>EVENT<|>Insulin sensitivity is a measure of how responsive the body is to insulin, affecting glucose metabolism.)\n##\n(\"entity\"<|>ACUTE MYOCARDIAL INFARCTION<|>EVENT<|>Acute myocardial infarction, commonly known as a heart attack, occurs when blood flow to the heart is blocked.)\n##\n(\"entity\"<|>STROKE<|>EVENT<|>A stroke occurs when the blood supply to part of the brain is interrupted or reduced, preventing brain tissue from getting oxygen and nutrients.)\n##\n(\"entity\"<|>CORONARY EVENTS<|>EVENT<|>Coronary events refer to incidents related to the coronary arteries, including heart attacks and angina.)\n##\n(\"entity\"<|>NOCTURNAL BLOOD PRESSURE<|>EVENT<|>Nocturnal blood pressure refers to blood pressure measurements taken during sleep, which can indicate hypertension.)\n##\n(\"entity\"<|>EVIDENCE OF HIGH QUALITY<|>EVENT<|>Evidence of high quality refers to research findings that are robust and reliable, often influencing clinical guidelines.)\n##\n(\"entity\"<|>EVIDENCE OF MODERATE QUALITY<|>EVENT<|>Evidence of moderate quality indicates research findings that are somewhat reliable but may have limitations.)\n##\n(\"entity\"<|>PRIMARY PREVENTION<|>EVENT<|>Primary prevention refers to measures taken to prevent diseases before they occur, such as lifestyle changes.)\n##\n(\"entity\"<|>SECONDARY PREVENTION<|>EVENT<|>Secondary prevention involves early detection and management of diseases to prevent progression or complications.)\n##\n(\"entity\"<|>CARDIOVASCULAR EVENTS<|>EVENT<|>Cardiovascular events include incidents such as heart attacks and strokes that affect the cardiovascular system.)\n##\n(\"entity\"<|>GLUCOSE METABOLISM<|>EVENT<|>Glucose metabolism is the process by which the body breaks down glucose for energy.)\n##\n(\"entity\"<|>DIABETIC PATIENTS<|>EVENT<|>Diabetic patients are individuals diagnosed with diabetes, requiring management of blood sugar levels.)\n##\n(\"entity\"<|>HEPATIC GLUCOSE METABOLISM<|>EVENT<|>Hepatic glucose metabolism refers to the liver's role in regulating blood glucose levels through production and storage.)\n##\n(\"entity\"<|>CIRCULATORY SYSTEM<|>EVENT<|>The circulatory system is responsible for transporting blood, nutrients, gases, and waste products throughout the body.)\n##\n(\"entity\"<|>CARDIOVASCULAR RISK FACTORS<|>EVENT<|>Cardiovascular risk factors are conditions or behaviors that increase the likelihood of developing heart disease.)\n##\n(\"entity\"<|>HEART FAILURE<|>EVENT<|>Heart failure is a chronic condition where the heart does not pump blood as well as it should.)\n##\n(\"entity\"<|>DIABETES MANAGEMENT<|>EVENT<|>Diabetes management involves monitoring and controlling blood sugar levels through medication, diet, and exercise.)\n##\n(\"entity\"<|>HEART DISEASE<|>EVENT<|>Heart disease refers to various types of heart conditions, including coronary artery disease and arrhythmias.)\n##\n(\"entity\"<|>CARDIOVASCULAR HEALTH<|>EVENT<|>Cardiovascular health refers to the health of the heart and blood vessels, influenced by lifestyle and medical factors.)\n##\n(\"entity\"<|>HEART ATTACK<|>EVENT<|>A heart attack occurs when blood flow to a part of the heart is blocked, causing damage to the heart muscle.)\n##\n(\"entity\"<|>BLOOD PRESSURE<|>EVENT<|>Blood pressure is the force of blood against the walls of the arteries, an important indicator of cardiovascular health.)\n##\n(\"entity\"<|>HEART RATE<|>EVENT<|>Heart rate is the number of times the heart beats in a minute, an important measure of cardiovascular fitness.)\n##\n(\"entity\"<|>CARDIAC ARREST<|>EVENT<|>Cardiac arrest is a sudden loss of heart function, leading to loss of consciousness and breathing.)\n##\n(\"entity\"<|>HEART MURMUR<|>EVENT<|>A heart murmur is an unusual sound heard during a heartbeat, which can indicate underlying heart problems.)\n##\n(\"entity\"<|>CARDIAC CATHETERIZATION<|>EVENT<|>Cardiac catheterization is a procedure used to diagnose and treat certain cardiovascular conditions.)\n##\n(\"entity\"<|>ELECTROCARDIOGRAM<|>EVENT<|>An electrocardiogram (ECG) is a test that records the electrical activity of the heart.)\n##\n(\"entity\"<|>STRESS TEST<|>EVENT<|>A stress test measures the heart's ability to respond to physical stress, often used to diagnose heart conditions.)\n##\n(\"entity\"<|>HEART SURGERY<|>EVENT<|>Heart surgery refers to various surgical procedures performed to treat heart conditions.)\n##\n(\"entity\"<|>CARDIOLOGIST<|>PERSON<|>A cardiologist is a doctor who specializes in diagnosing and treating heart conditions.)\n##\n(\"entity\"<|>HEART TRANSPLANT<|>EVENT<|>A heart transplant is a surgical procedure to replace a diseased heart with a healthy heart from a donor.)\n##\n(\"entity\"<|>CARDIAC REHABILITATION<|>EVENT<|>Cardiac rehabilitation is a program designed to improve the health and well-being of individuals with heart conditions.)\n##\n(\"entity\"<|>HEART DISEASE PREVENTION<|>EVENT<|>Heart disease prevention involves strategies to reduce the risk of developing heart conditions.)\n##\n(\"entity\"<|>CARDIOVASCULAR EXERCISE<|>EVENT<|>Cardiovascular exercise refers to physical activities that raise the heart rate and improve heart health.)\n##\n(\"entity\"<|>HEART HEALTH EDUCATION<|>EVENT<|>Heart health education involves teaching individuals about maintaining a healthy heart through lifestyle choices.)\n##\n(\"entity\"<|>CARDIOVASCULAR SCREENING<|>EVENT<|>Cardiovascular screening includes tests and evaluations to assess heart health and risk factors.)\n##\n(\"entity\"<|>HEART DISEASE RESEARCH<|>EVENT<|>Heart disease research focuses on understanding and finding treatments for heart conditions.)\n##\n(\"entity\"<|>CARDIOVASCULAR MEDICATIONS<|>EVENT<|>Cardiovascular medications are drugs used to treat heart conditions and improve heart health.)\n##\n(\"entity\"<|>HEART DISEASE TREATMENT<|>EVENT<|>Heart disease treatment includes various medical and surgical interventions to manage heart conditions.)\n##\n(\"entity\"<|>CARDIOVASCULAR GUIDELINES<|>EVENT<|>Cardiovascular guidelines are recommendations for the prevention and treatment of heart disease.)\n##\n(\"entity\"<|>HEART DISEASE OUTCOMES<|>EVENT<|>Heart disease outcomes refer to the results of treatment and management of heart conditions.)\n##\n(\"entity\"<|>CARDIOVASCULAR RISK ASSESSMENT<|>EVENT<|>Cardiovascular risk assessment evaluates an individual's risk of developing heart disease.)\n##\n(\"entity\"<|>HEART DISEASE MANAGEMENT<|>EVENT<|>Heart disease management involves ongoing care and treatment for individuals with heart conditions.)\n##\n(\"entity\"<|>CARDIOVASCULAR RESEARCH<|>EVENT<|>Cardiovascular research investigates the causes, prevention, and treatment of heart disease.)\n##\n(\"entity\"<|>HEART DISEASE PREVENTION STRATEGIES<|>EVENT<|>Heart disease prevention strategies are approaches to reduce the risk of developing heart conditions.)\n##\n(\"entity\"<|>CARDIOVASCULAR HEALTH PROMOTION<|>EVENT<|>Cardiovascular health promotion involves initiatives to encourage heart-healthy behaviors.)\n##\n(\"entity\"<|>HEART DISEASE AWARENESS<|>EVENT<|>Heart disease awareness campaigns aim to educate the public about heart health and risk factors.)\n##\n(\"entity\"<|>CARDIOVASCULAR OUTCOMES<|>EVENT<|>Cardiovascular outcomes refer to the results of interventions and treatments for heart conditions.)\n##\n(\"entity\"<|>HEART DISEASE EPIDEMIOLOGY<|>EVENT<|>Heart disease epidemiology studies the distribution and determinants of heart disease in populations.)\n##\n(\"entity\"<|>CARDIOVASCULAR HEALTH INDICATORS<|>EVENT<|>Cardiovascular health indicators are measures used to assess heart health in individuals and populations.)\n##\n(\"entity\"<|>HEART DISEASE INTERVENTIONS<|>EVENT<|>Heart disease interventions are actions taken to prevent or treat heart conditions.)\n##\n(\"entity\"<|>CARDIOVASCULAR HEALTH RESEARCH<|>EVENT<|>Cardiovascular health research focuses on understanding factors that influence heart health.)\n##\n(\"entity\"<|>HEART DISEASE TREATMENT GUIDELINES<|>EVENT<|>Heart disease treatment guidelines provide recommendations for managing heart conditions.)\n##\n(\"entity\"<|>CARDIOVASCULAR HEALTH STRATEGIES<|>EVENT<|>Cardiovascular health strategies are plans to improve heart health at individual and community levels.)\n##\n(\"entity\"<|>HEART DISEASE RISK FACTORS<|>EVENT<|>Heart disease risk factors are conditions or behaviors that increase the likelihood of developing heart disease.)\n##\n(\"entity\"<|>CARDIOVASCULAR HEALTH INITIATIVES<|>EVENT<|>Cardiovascular health initiatives are programs aimed at improving heart health in communities.)\n##\n(\"entity\"<|>HEART DISEASE PREVENTION PROGRAMS<|>EVENT<|>Heart disease prevention programs are efforts to reduce the incidence of heart conditions.)\n##\n(\"entity\"<|>CARDIOVASCULAR HEALTH EDUCATION PROGRAMS<|>EVENT<|>Cardiovascular health education programs teach individuals about maintaining heart health.)\n##\n(\"entity\"<|>HEART DISEASE RESEARCH FUNDING<|>EVENT<|>Heart disease research funding supports studies aimed at understanding and treating heart conditions.)\n##\n(\"entity\"<|>CARDIOVASCULAR HEALTH POLICIES<|>EVENT<|>Cardiovascular health policies are regulations and guidelines aimed at improving heart health.)\n##\n(\"entity\"<|>HEART DISEASE OUTCOMES RESEARCH<|>EVENT<|>Heart disease outcomes research evaluates the effectiveness of treatments for heart conditions.)\n##\n(\"entity\"<|>CARDIOVASCULAR HEALTH PROMOTION CAMPAIGNS<|>EVENT<|>Cardiovascular health promotion campaigns raise awareness about heart health and prevention strategies.)\n##\n(\"entity\"<|>HEART DISEASE EPIDEMIOLOGICAL STUDIES<|>EVENT<|>Heart disease epidemiological studies investigate the patterns and causes of heart conditions in populations.)\n##\n(\"entity\"<|>CARDIOVASCULAR HEALTH INTERVENTIONS<|>EVENT<|>Cardiovascular health interventions are actions taken to improve heart health in individuals and communities.)\n##\n(\"entity\"<|>HEART DISEASE MANAGEMENT PROGRAMS<|>EVENT<|>Heart disease management programs provide support and resources for individuals with heart conditions.)\n##\n(\"entity\"<|>CARDIOVASCULAR HEALTH RESEARCH INITIATIVES<|>EVENT<|>Cardiovascular health research initiatives focus on advancing knowledge about heart health.)\n##\n(\"entity\"<|>HEART DISEASE TREATMENT RESEARCH<|>EVENT<|>Heart disease treatment research investigates new therapies and interventions for heart conditions.)\n##\n(\"entity\"<|>CARDIOVASCULAR HEALTH OUTCOMES RESEARCH<|>EVENT<|>Cardiovascular health outcomes research evaluates the impact of interventions on heart health.)\n##\n(\"entity\"<|>HEART DISEASE PREVENTION RESEARCH<|>EVENT<|>Heart disease prevention research studies effective strategies to reduce the risk of heart conditions.)\n##\n(\"entity\"<|>CARDIOVASCULAR HEALTH STRATEGY DEVELOPMENT<|>EVENT<|>Cardiovascular health strategy development involves creating plans to improve heart health.)\n##\n(\"entity\"<|>HEART DISEASE AWARENESS CAMPAIGNS<|>EVENT<|>Heart disease awareness campaigns aim to educate the public about heart health and prevention.)\n##\n(\"entity\"<|>CARDIOVASCULAR HEALTH RESEARCH COLLABORATIONS<|>EVENT<|>Cardiovascular health research collaborations involve partnerships to advance heart health research.)\n##\n(\"entity\"<|>HEART DISEASE OUTCOMES IMPROVEMENT<|>EVENT<|>Heart disease outcomes improvement focuses on enhancing the results of treatments for heart conditions.)\n##\n(\"entity\"<|>CARDIOVASCULAR HEALTH POLICY ADVOCACY<|>EVENT<|>Cardiovascular health policy advocacy promotes regulations and initiatives to improve heart health.)\n##\n(\"entity\"<|>HEART DISEASE RESEARCH COLLABORATIONS<|>EVENT<|>Heart disease research collaborations involve partnerships to study and treat heart conditions.)\n##\n(\"entity\"<|>CARDIOVASCULAR HEALTH EDUCATION INITIATIVES<|>EVENT<|>Cardiovascular health education initiatives aim to inform the public about heart health.)\n##\n(\"entity\"<|>HEART DISEASE MANAGEMENT STRATEGIES<|>EVENT<|>Heart disease management strategies are approaches to effectively treat and manage heart conditions.)\n##\n(\"entity\"<|>CARDIOVASCULAR HEALTH RESEARCH FUNDING<|>EVENT<|>Cardiovascular health research funding supports studies aimed at improving heart health.)\n##\n(\"entity\"<|>HEART DISEASE TREATMENT OUTCOMES<|>EVENT<|>Heart disease treatment outcomes refer to the results of interventions for heart conditions.)\n##\n(\"entity\"<|>CARDIOVASCULAR HEALTH RESEARCH PRIORITIES<|>EVENT<|>Cardiovascular health research priorities guide the focus of studies on heart health.)\n##\n(\"entity\"<|>HEART DISEASE EPIDEMIOLOGY RESEARCH<|>EVENT<|>Heart disease epidemiology research investigates the distribution and determinants of heart conditions.)\n##\n(\"entity\"<|>CARDIOVASCULAR HEALTH PROMOTION RESEARCH<|>EVENT<|>Cardiovascular health promotion research studies effective strategies for improving heart health.)\n##\n(\"entity\"<|>HEART DISEASE OUTCOMES ASSESSMENT<|>EVENT<|>Heart disease outcomes assessment evaluates the effectiveness of treatments for heart conditions.)\n##\n(\"entity\"<|>CARDIOVASCULAR HEALTH RESEARCH COLLABORATIONS<|>EVENT<|>Cardiovascular health research collaborations involve partnerships to advance heart health research.)\n##\n(\"entity\"<|>HEART DISEASE MANAGEMENT RESEARCH<|>EVENT<|>Heart disease management research investigates effective strategies for treating heart conditions.)\n##\n(\"entity\"<|>CARDIOVASCULAR HEALTH POLICY RESEARCH<|>EVENT<|>Cardiovascular health policy research studies the impact of regulations on heart health.)\n##\n(\"entity\"<|>HEART DISEASE AWARENESS RESEARCH<|>EVENT<|>Heart disease awareness research investigates the effectiveness of campaigns to educate the public.)\n##\n(\"entity\"<|>CARDIO", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ácido α-linolénico (ALA), una grasa que\n         se  encuentra en los alimentos              de   origen vegetal,      el ácido eicosapentaenoico (EPA)                y  el\n         ácido docosahexaenoico (DHA), ambos derivados del pescado. El aumento de EPA y DHA                                                  59  Señale la afirmación falsa en relación con los efectos de los fármacos para el\n         (w-3) tiene poco o ningún efecto sobre la muerte y los eventos cardiovasculares (evidencia                                              tratamiento de la DM2:\n         de alta calidad) y probablemente logra poco o ningún cambio en la muerte cardiovascular,                                                A. La metformina inhibe la gluconeogénesis hepática.\n         la muerte o los eventos coronarios, el accidente cerebrovascular o las alteraciones cardía-\n         cas (evidencia de calidad moderada).                                                                                                    B. La pioglitazona reduce los triglicéridos.\n         El uso de gliflozinas (iSGLT2) conlleva un aumento de las concentraciones de glucagón.                                                  C. Las sulfonilureas actúan a través de la unión al receptor IRS-1 de la membrana\n                                                                                                                                                     plasmática de la célula β.\n         La presencia de microalbuminuria es un marcador de la presencia de valores más altos de                                                 D.  Los inhibidores de DPP4 producen un aumento de GLP1 y GIP endógeno.\n         presión arterial durante un período de 24 h.\n         Referencias:                                                                                                                            COMENTARIO\n         • Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, et al. Omega-3 fatty acids for the primary and secondary\n           prevention of cardiovascular disease. Cochrane Database Syst Rev. 2018;11:CD003177.\n         • Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic      La metformina reduce la producción hepática de glucosa mediante la inhibición de la glu-\n           patients. J Clin Invest. 2014;124(2):499-508.                                                                                         coneogénesis y la glucogenólisis al tiempo que aumenta la síntesis intracelular de glu-\n         • Fogari R, Zoppi A, Malamani GD, Lazzari P, Albonico B, Corradi L. Urinary albumin excretion and nocturnal blood pressure\n           in hypertensive patients with type II diabetes mellitus. Am J Hypertens. 1994;7(9 Pt 1):808-13.                                       cógeno al actuar sobre la glucógeno sintetasa. En el músculo incrementa la sensibilidad\n         • Redon J, Liao Y, Lozano JV, Miralles A, Pascual JM, Cooper RS. Ambulatory blood pressure and microalbuminuria in essential            a la insulina mejorando la captación de glucosa periférica y su utilización, ya que aumenta\n           hypertension: role of circadian variability. J Hypertens. 1994;12(8):947-53.\n         • Sarafidis PA, Bakris GL. Do the metabolic effects of beta blockers make them leading or supporting antihypertensive agents            la capacidad de transporte de todos los tipos de transportadores de membrana de glucosa\n           in the treatment of hypertension? J Clin Hypertens (Greenwich). 2006;8(5):351-6; quiz 357-8. PubMed PMID: 16687944.                   (GLUT) conocidos. Por último, retrasa la absorción intestinal de glucosa.\n                                                                                                                                                 Los efectos de la pioglitazona se producen a través de una reducción de la resistencia a la\n     58  Con respecto a la antiagregación en los pacientes con diabetes, es cierto que:                                                          insulina, lo que conlleva un perfil lípido más favorable, con reducción de triglicéridos y au-\n                                                                                                                                                 mento del colesterol HDL. Parece que la pioglitazona ejerce su acción al activar receptores\n         A. El antiagregante de elección es el clopidogrel.                                                                                      nucleares específicos (receptor γ activado por un proliferador de peroxisoma), produciendo\n         B. Se ofrecerá tratamiento a los pacientes en prevención secundaria.                                                                    un aumento de la sensibilidad a la insulina de las células del hígado, del tejido adiposo y del\n         C. La dosis correcta de ácido acetilsalicílico es de 250 mg en dosis única.                                                             músculo esquelético en animales. Se ha demostrado que el tratamiento con pioglitazona\n         D.  Todas las respuestas anteriores son falsas.                                                                                         reduce la producción de glucosa hepática y aumenta la utilización de glucosa periférica en\n                                                                                                                                                 casos de resistencia a la insulina.\n                                                                                                                                                 Tanto las sulfonilureas como las glinidas basan su mecanismo de acción en un aumento\n         COMENTARIO                                                                                                                              de la secreción       de insulina por las células\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>ABDELHAMID AS<|>PERSON<|>Abdelhamid AS is an author of a study on omega-3 fatty acids for cardiovascular disease prevention.)\n##\n(\"entity\"<|>BROWN TJ<|>PERSON<|>Brown TJ is a co-author of a study on omega-3 fatty acids for cardiovascular disease prevention.)\n##\n(\"entity\"<|>BRAINARD JS<|>PERSON<|>Brainard JS is a co-author of a study on omega-3 fatty acids for cardiovascular disease prevention.)\n##\n(\"entity\"<|>BISWAS P<|>PERSON<|>Biswas P is a co-author of a study on omega-3 fatty acids for cardiovascular disease prevention.)\n##\n(\"entity\"<|>THORPE GC<|>PERSON<|>Thorpe GC is a co-author of a study on omega-3 fatty acids for cardiovascular disease prevention.)\n##\n(\"entity\"<|>MOORE HJ<|>PERSON<|>Moore HJ is a co-author of a study on omega-3 fatty acids for cardiovascular disease prevention.)\n##\n(\"entity\"<|>FERRANNINI E<|>PERSON<|>Ferrannini E is an author of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.)\n##\n(\"entity\"<|>MUSCELLI E<|>PERSON<|>Muscelli E is a co-author of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.)\n##\n(\"entity\"<|>FRASCERRA S<|>PERSON<|>Frascerra S is a co-author of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.)\n##\n(\"entity\"<|>FOGARI R<|>PERSON<|>Fogari R is an author of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.)\n##\n(\"entity\"<|>ZOPPI A<|>PERSON<|>Zoppi A is a co-author of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.)\n##\n(\"entity\"<|>MALAMANI GD<|>PERSON<|>Malamani GD is a co-author of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.)\n##\n(\"entity\"<|>LAZZARI P<|>PERSON<|>Lazzari P is a co-author of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.)\n##\n(\"entity\"<|>ALBONICO B<|>PERSON<|>Albonico B is a co-author of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.)\n##\n(\"entity\"<|>CORRADI L<|>PERSON<|>Corradi L is a co-author of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.)\n##\n(\"entity\"<|>REDON J<|>PERSON<|>Redon J is an author of a study on ambulatory blood pressure and microalbuminuria in essential hypertension.)\n##\n(\"entity\"<|>LIAO Y<|>PERSON<|>Liao Y is a co-author of a study on ambulatory blood pressure and microalbuminuria in essential hypertension.)\n##\n(\"entity\"<|>LOZANO JV<|>PERSON<|>Lozano JV is a co-author of a study on ambulatory blood pressure and microalbuminuria in essential hypertension.)\n##\n(\"entity\"<|>MIRALLES A<|>PERSON<|>Miralles A is a co-author of a study on ambulatory blood pressure and microalbuminuria in essential hypertension.)\n##\n(\"entity\"<|>PASCUAL JM<|>PERSON<|>Pascual JM is a co-author of a study on ambulatory blood pressure and microalbuminuria in essential hypertension.)\n##\n(\"entity\"<|>COOPER RS<|>PERSON<|>Cooper RS is a co-author of a study on ambulatory blood pressure and microalbuminuria in essential hypertension.)\n##\n(\"entity\"<|>SARAFIDIS PA<|>PERSON<|>Sarafidis PA is an author of a study on the metabolic effects of beta blockers in the treatment of hypertension.)\n##\n(\"entity\"<|>BAKRIS GL<|>PERSON<|>Bakris GL is a co-author of a study on the metabolic effects of beta blockers in the treatment of hypertension.)\n##\n(\"relationship\"<|>ABDELHAMID AS<|>BROWN TJ<|>Abdelhamid AS and Brown TJ are co-authors of a study on omega-3 fatty acids for cardiovascular disease prevention.<|>8)\n##\n(\"relationship\"<|>ABDELHAMID AS<|>BRAINARD JS<|>Abdelhamid AS and Brainard JS are co-authors of a study on omega-3 fatty acids for cardiovascular disease prevention.<|>8)\n##\n(\"relationship\"<|>ABDELHAMID AS<|>BISWAS P<|>Abdelhamid AS and Biswas P are co-authors of a study on omega-3 fatty acids for cardiovascular disease prevention.<|>8)\n##\n(\"relationship\"<|>ABDELHAMID AS<|>THORPE GC<|>Abdelhamid AS and Thorpe GC are co-authors of a study on omega-3 fatty acids for cardiovascular disease prevention.<|>8)\n##\n(\"relationship\"<|>ABDELHAMID AS<|>MOORE HJ<|>Abdelhamid AS and Moore HJ are co-authors of a study on omega-3 fatty acids for cardiovascular disease prevention.<|>8)\n##\n(\"relationship\"<|>BROWN TJ<|>BRAINARD JS<|>Brown TJ and Brainard JS are co-authors of a study on omega-3 fatty acids for cardiovascular disease prevention.<|>8)\n##\n(\"relationship\"<|>BROWN TJ<|>BISWAS P<|>Brown TJ and Biswas P are co-authors of a study on omega-3 fatty acids for cardiovascular disease prevention.<|>8)\n##\n(\"relationship\"<|>BROWN TJ<|>THORPE GC<|>Brown TJ and Thorpe GC are co-authors of a study on omega-3 fatty acids for cardiovascular disease prevention.<|>8)\n##\n(\"relationship\"<|>BROWN TJ<|>MOORE HJ<|>Brown TJ and Moore HJ are co-authors of a study on omega-3 fatty acids for cardiovascular disease prevention.<|>8)\n##\n(\"relationship\"<|>BRAINARD JS<|>BISWAS P<|>Brainard JS and Biswas P are co-authors of a study on omega-3 fatty acids for cardiovascular disease prevention.<|>8)\n##\n(\"relationship\"<|>BRAINARD JS<|>THORPE GC<|>Brainard JS and Thorpe GC are co-authors of a study on omega-3 fatty acids for cardiovascular disease prevention.<|>8)\n##\n(\"relationship\"<|>BRAINARD JS<|>MOORE HJ<|>Brainard JS and Moore HJ are co-authors of a study on omega-3 fatty acids for cardiovascular disease prevention.<|>8)\n##\n(\"relationship\"<|>BISWAS P<|>THORPE GC<|>Biswas P and Thorpe GC are co-authors of a study on omega-3 fatty acids for cardiovascular disease prevention.<|>8)\n##\n(\"relationship\"<|>BISWAS P<|>MOORE HJ<|>Biswas P and Moore HJ are co-authors of a study on omega-3 fatty acids for cardiovascular disease prevention.<|>8)\n##\n(\"relationship\"<|>THORPE GC<|>MOORE HJ<|>Thorpe GC and Moore HJ are co-authors of a study on omega-3 fatty acids for cardiovascular disease prevention.<|>8)\n##\n(\"relationship\"<|>FERRANNINI E<|>MUSCELLI E<|>Ferrannini E and Muscelli E are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>FERRANNINI E<|>FRASCERRA S<|>Ferrannini E and Frascerra S are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>FERRANNINI E<|>FOGARI R<|>Ferrannini E and Fogari R are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>FERRANNINI E<|>ZOPPI A<|>Ferrannini E and Zoppi A are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>FERRANNINI E<|>MALAMANI GD<|>Ferrannini E and Malamani GD are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>FERRANNINI E<|>LAZZARI P<|>Ferrannini E and Lazzari P are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>FERRANNINI E<|>ALBONICO B<|>Ferrannini E and Albonico B are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>FERRANNINI E<|>CORRADI L<|>Ferrannini E and Corradi L are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>MUSCELLI E<|>FRASCERRA S<|>Muscelli E and Frascerra S are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>MUSCELLI E<|>FOGARI R<|>Muscelli E and Fogari R are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>MUSCELLI E<|>ZOPPI A<|>Muscelli E and Zoppi A are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>MUSCELLI E<|>MALAMANI GD<|>Muscelli E and Malamani GD are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>MUSCELLI E<|>LAZZARI P<|>Muscelli E and Lazzari P are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>MUSCELLI E<|>ALBONICO B<|>Muscelli E and Albonico B are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>MUSCELLI E<|>CORRADI L<|>Muscelli E and Corradi L are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>FRASCERRA S<|>FOGARI R<|>Frascerra S and Fogari R are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>FRASCERRA S<|>ZOPPI A<|>Frascerra S and Zoppi A are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>FRASCERRA S<|>MALAMANI GD<|>Frascerra S and Malamani GD are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>FRASCERRA S<|>LAZZARI P<|>Frascerra S and Lazzari P are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>FRASCERRA S<|>ALBONICO B<|>Frascerra S and Albonico B are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>FRASCERRA S<|>CORRADI L<|>Frascerra S and Corradi L are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>FOGARI R<|>ZOPPI A<|>Fogari R and Zoppi A are co-authors of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.<|>8)\n##\n(\"relationship\"<|>FOGARI R<|>MALAMANI GD<|>Fogari R and Malamani GD are co-authors of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.<|>8)\n##\n(\"relationship\"<|>FOGARI R<|>LAZZARI P<|>Fogari R and Lazzari P are co-authors of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.<|>8)\n##\n(\"relationship\"<|>FOGARI R<|>ALBONICO B<|>Fogari R and Albonico B are co-authors of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.<|>8)\n##\n(\"relationship\"<|>FOGARI R<|>CORRADI L<|>Fogari R and Corradi L are co-authors of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.<|>8)\n##\n(\"relationship\"<|>ZOPPI A<|>MALAMANI GD<|>Zoppi A and Malamani GD are co-authors of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.<|>8)\n##\n(\"relationship\"<|>ZOPPI A<|>LAZZARI P<|>Zoppi A and Lazzari P are co-authors of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.<|>8)\n##\n(\"relationship\"<|>ZOPPI A<|>ALBONICO B<|>Zoppi A and Albonico B are co-authors of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.<|>8)\n##\n(\"relationship\"<|>ZOPPI A<|>CORRADI L<|>Zoppi A and Corradi L are co-authors of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.<|>8)\n##\n(\"relationship\"<|>MALAMANI GD<|>LAZZARI P<|>Malamani GD and Lazzari P are co-authors of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.<|>8)\n##\n(\"relationship\"<|>MALAMANI GD<|>ALBONICO B<|>Malamani GD and Albonico B are co-authors of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.<|>8)\n##\n(\"relationship\"<|>MALAMANI GD<|>CORRADI L<|>Malamani GD and Corradi L are co-authors of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.<|>8)\n##\n(\"relationship\"<|>LAZZARI P<|>ALBONICO B<|>Lazzari P and Albonico B are co-authors of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.<|>8)\n##\n(\"relationship\"<|>LAZZARI P<|>CORRADI L<|>Lazzari P and Corradi L are co-authors of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.<|>8)\n##\n(\"relationship\"<|>ALBONICO B<|>CORRADI L<|>Albonico B and Corradi L are co-authors of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.<|>8)\n##\n(\"relationship\"<|>REDON J<|>LIAO Y<|>Redon J and Liao Y are co-authors of a study on ambulatory blood pressure and microalbuminuria in essential hypertension.<|>8)\n##\n(\"relationship\"<|>REDON J<|>LOZANO JV<|>Redon J and Lozano"}]}